Open
Actively Recruiting
SPECT/CT for the Characterization of Renal Masses
About
Brief Summary
This trial studies how well technetium Tc-99m sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) works on clinical decision making in patients with kidney tumors. Diagnostic procedures, such as technetium Tc-99m sestamibi SPECT/CT may be a less invasive way to check for kidney tumors.
Study Type
Phase
Eligibility
Gender
Healthy Volunteers
Minimum Age
Maximum Age
Inclusion Criteria:
- Performance status Eastern Cooperative Oncology Group (ECOG) < 2.
- Life expectancy (> 1 year).
- New diagnosis of a renal tumor (within past 3 months).
- Measurable, predominantly (> 80%) solid renal neoplasm between 1.5-5.0 cm.
- Lesion concerning for kidney cancer bases on a contrast-enhanced CT or magnetic resonance imaging (MRI).
- No definitive evidence of metastatic disease.
- Does not require urgent surgical treatment.
- Candidate for surgical, ablative, and surveillance approach.
- Willingness to obtain more information to aid decision-making.
- Understanding and willingness to provide consent.
Exclusion Criteria:
- Presence of multiple solid renal tumors.
- A prior needle biopsy of the mass resulting in histologic diagnosis.
- A prior diagnosis of kidney cancer.
- Presence of an active, untreated, non-renal malignancy.
- History of bleeding diathesis or recent bleeding episode.
- Prior surgery or radiation therapy to the kidney.
- Unwillingness to fill out questionnaires.
Join this Trial
Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-001817
Category
Kidney Cancer
Principal Investigator
Contact
Location
- UCLA Santa Monica
- UCLA Westwood